Healthcare / Drug Manufacturers - Specialty & GenericSão Paulo
$10.56
-0.09 (-0.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $134.1M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
11.2x
↓EV/EBITDA
5.7x
↓ROE
13.0%
↑Gross Margin
40.1%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.6%
FCF CAGR
-0.1%
FCF margin
7.9%
FCF / Net income
0.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.70B · net income $295.0M · FCF $134.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.70B | $1.70B | $1.75B | $1.37B | $1.41B |
| Net Income | $295.0M | $295.0M | $217.2M | $249.8M | $363.4M |
| EBITDA | $529.8M | $529.8M | $402.0M | $405.2M | $523.3M |
| EPS | 1.28 | 1.28 | 0.94 | 1.08 | 1.57 |
| Gross Margin | 40.1% | 40.1% | 37.5% | 35.7% | 47.5% |
| Operating Margin | 20.8% | 20.8% | 18.6% | 24.4% | 32.0% |
| Net Margin | 17.3% | 17.3% | 12.4% | 18.2% | 25.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.26 | 0.30 | 0.17 |
| Current Ratio | 2.66 | 2.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $134.1M | $134.1M | $366.1M | $105.6M | $134.4M |
| Returns | |||||
| ROE | 13.0% | 13.0% | 10.0% | 12.5% | 19.9% |
| Valuation | |||||
| P/E | 11.23 | 11.23 | 10.57 | 10.87 | 12.84 |
| EV/EBITDA | 5.69 | 5.69 | 7.02 | 8.21 | 9.55 |
| P/B | 1.08 | 1.08 | 1.06 | 1.37 | 2.58 |
| Growth & Yield | |||||
| Revenue Growth | -3.0% | -3.0% | 27.8% | -2.4% | — |
| EPS Growth | 36.4% | 36.4% | -13.5% | -30.9% | — |
| Dividend Yield | 6.3% | 6.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-9.9%
EPS terminal req.
$0.94
Spread vs growth
46.3%
5Y implied EPS CAGR
-2.4%
EPS terminal req.
$1.13
Spread vs growth
38.8%
10Y implied EPS CAGR
3.6%
EPS terminal req.
$1.83
Spread vs growth
32.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.3%
Start / end P/E
11.5x → 8.3x
EPS bridge
0.94 → 1.28
Residual
-10.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.